PAFSC 2nd Committee to Review 5 Products Including Novartis’s COPD Drug on Sept. 6

The Pharmaceutical Affairs and Food Sanitation Council’s (PAFSC) Second Committee on Drugs will review five products/indications, including Novartis Pharma’s chronic obstructive pulmonary disease (COPD) treatment glycopyrronium bromide on September 6. Glycopyrronium bromide is a long-acting anticholine bronchodilator inhaled once daily...read more